id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-E-0381-0008,FDA,FDA-2006-E-0381,"Certificate Extending Patent Term from U.S. Patent and Trademark Office to Amylin Pharmaceuticals, Inc.",Rule,Certificate Extending Patent Term,2007-10-23T04:00:00Z,2007,10,,,2025-12-11T01:22:08Z,,0,0,090000648046034f
FDA-2006-E-0381-0007,FDA,FDA-2006-E-0381,"Notice of Final Determination from U.S. Patent and Trademark Office to Amylin Pharmaceuticals, Inc.",Other,Letter(s),2007-04-13T04:00:00Z,2007,4,,,2025-12-11T01:21:00Z,,0,0,090000648046034e
FDA-2006-E-0381-0006,FDA,FDA-2006-E-0381,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2007-01-10T05:00:00Z,2007,1,,,2025-12-11T01:07:05Z,,0,0,090000648046034d
FDA-2006-E-0381-0005,FDA,FDA-2006-E-0381,Determination of Regulatory Review Period for Purposes of Patent Extension; SYMLIN,Notice,General Notice,2006-06-19T04:00:00Z,2006,6,2006-06-16T04:00:00Z,,2025-12-11T01:05:26Z,E6-9414,0,0,090000648046034c
FDA-2006-E-0381-0003,FDA,FDA-2006-E-0381,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-05-25T04:00:00Z,2006,5,,,2025-12-11T00:30:44Z,,0,0,090000648046034a
FDA-2006-E-0381-0004,FDA,FDA-2006-E-0381,Letter from FDA CDER to U. S.  Patent and Trademark Office,Other,Letter(s),2006-05-25T04:00:00Z,2006,5,,,2025-12-11T00:32:17Z,,0,0,090000648046034b
FDA-2006-E-0381-0002,FDA,FDA-2006-E-0381,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-02-27T05:00:00Z,2006,2,,,2025-12-11T00:20:23Z,,0,0,0900006480460349
FDA-2006-E-0381-0001,FDA,FDA-2006-E-0381,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-01-12T05:00:00Z,2006,1,,,2025-12-11T00:18:22Z,,0,0,090000648046032b